中国医学装备
中國醫學裝備
중국의학장비
CHINA MEDICAL EQUIPMENT
2015年
8期
92-94,95
,共4页
颈动脉粥样硬化%瑞舒伐他汀%普罗布考
頸動脈粥樣硬化%瑞舒伐他汀%普囉佈攷
경동맥죽양경화%서서벌타정%보라포고
Carotid atherosclerosis%Rosuvastatin%Probucol
目的：分析瑞舒伐他汀与普罗布考联合用药在颈动脉粥样硬化斑块治疗中的应用价值。方法：选择118例接受住院治疗的颈动脉粥样硬化斑块患者，将其随机分为对照组和观察组，每组59例。对照组接受单纯普罗布考治疗，观察组接受瑞舒伐他汀联合普罗布考治疗，比较两组患者的颈动脉内膜中层厚度(IMT)及血浆氧化低密度脂蛋白(OX-LDL)水平、炎症因子水平以及不良事件发生率等差异。结果：①观察组患者治疗后的IMT与OX-LDL水平均明显低于对照组患者，差异有统计学意义(t=4.327，t=5.783；P＜0.05)；②观察组患者治疗后的超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)及基质金属蛋白酶-9(MMP-9)水平均显著低于对照组患者，差异有统计学意义(t=6.422，t=5.184，t=5.291；P＜0.05)；③随访5年内，观察组患者发生血管闭塞、斑块脱落及脑梗死等不良事件的概率明显低于对照组患者，差异有统计学意义(x2=4.827， x2=5.894，x2=5.937；P＜0.05)。结论：瑞舒伐他汀联合普罗布考可以有效减少IMT，降低OX-LDL及优化炎症因子水平，最终降低不良事件发生率，具有积极的临床意义。
目的：分析瑞舒伐他汀與普囉佈攷聯閤用藥在頸動脈粥樣硬化斑塊治療中的應用價值。方法：選擇118例接受住院治療的頸動脈粥樣硬化斑塊患者，將其隨機分為對照組和觀察組，每組59例。對照組接受單純普囉佈攷治療，觀察組接受瑞舒伐他汀聯閤普囉佈攷治療，比較兩組患者的頸動脈內膜中層厚度(IMT)及血漿氧化低密度脂蛋白(OX-LDL)水平、炎癥因子水平以及不良事件髮生率等差異。結果：①觀察組患者治療後的IMT與OX-LDL水平均明顯低于對照組患者，差異有統計學意義(t=4.327，t=5.783；P＜0.05)；②觀察組患者治療後的超敏C反應蛋白(hs-CRP)、白介素-6(IL-6)及基質金屬蛋白酶-9(MMP-9)水平均顯著低于對照組患者，差異有統計學意義(t=6.422，t=5.184，t=5.291；P＜0.05)；③隨訪5年內，觀察組患者髮生血管閉塞、斑塊脫落及腦梗死等不良事件的概率明顯低于對照組患者，差異有統計學意義(x2=4.827， x2=5.894，x2=5.937；P＜0.05)。結論：瑞舒伐他汀聯閤普囉佈攷可以有效減少IMT，降低OX-LDL及優化炎癥因子水平，最終降低不良事件髮生率，具有積極的臨床意義。
목적：분석서서벌타정여보라포고연합용약재경동맥죽양경화반괴치료중적응용개치。방법：선택118례접수주원치료적경동맥죽양경화반괴환자，장기수궤분위대조조화관찰조，매조59례。대조조접수단순보라포고치료，관찰조접수서서벌타정연합보라포고치료，비교량조환자적경동맥내막중층후도(IMT)급혈장양화저밀도지단백(OX-LDL)수평、염증인자수평이급불량사건발생솔등차이。결과：①관찰조환자치료후적IMT여OX-LDL수평균명현저우대조조환자，차이유통계학의의(t=4.327，t=5.783；P＜0.05)；②관찰조환자치료후적초민C반응단백(hs-CRP)、백개소-6(IL-6)급기질금속단백매-9(MMP-9)수평균현저저우대조조환자，차이유통계학의의(t=6.422，t=5.184，t=5.291；P＜0.05)；③수방5년내，관찰조환자발생혈관폐새、반괴탈락급뇌경사등불량사건적개솔명현저우대조조환자，차이유통계학의의(x2=4.827， x2=5.894，x2=5.937；P＜0.05)。결론：서서벌타정연합보라포고가이유효감소IMT，강저OX-LDL급우화염증인자수평，최종강저불량사건발생솔，구유적겁적림상의의。
Objective:To analyze the effect of rosuvastatin combination probucol on patients with carotid atherosclerotic plaque.Methods:Chosen patients with carotid atherosclerotic plaque in our hospital as research subjects, randomly assigned to control group received probucol alone and observation group received rosuvastatin combined probucol, compared IMT and OX-LDL levels inflammatory factors levels, incidence of adverse. Results:1)Observation group patients’ IMT and ox-LDL levels after treatment were significantly lower than control group patients(t=4.327,t=5.783;P<0.05); 2)Observation group patients’ hs-CRP, IL-6 and MMP-9 levels after treatment were significantly lower than control group patients (t=6.422,t=5.184,t=5.291;P<0.05); 3)Follow-up of 5 years, observation group patients vascular occlusion, plaque off , brain stem rate were significantly lower than control group patients (x2=4.827, x2=5.894,x2=5.937;P<0.05).Conclusion: Rosuvastatin can effectively reduce joint Probucol carotid atherosclerosis intima-media thickness sclerosis patients and reduce the level of oxidized LDL, inflammatory cytokines optimization, and ultimately reduce the incidence of adverse events, with positive clinical significance.
